orally delivered sirna targeting macrophage map4k4 suppresses systemic inflammation 
gene silencing double-stranded rna denoted rna interference represents new paradigm rational drug design1 however transformative therapeutic potential short interfering rna sirna stymied key obstacle-safe delivery specified target cells vivo2 macrophages particularly attractive targets rna interference therapy promote pathogenic inflammatory responses diseases rheumatoid arthritis atherosclerosis inflammatory bowel disease diabetes3 report engineering beta -d-glucan-encapsulated sirna particles gerps efficient oral delivery vehicles potently silence genes mouse macrophages vitro vivo oral gavage mice gerps containing little mu g kg- sirna directed tumour necrosis factor alpha tnf-alpha depleted messenger rna macrophages recovered peritoneum spleen liver lung lowered serum tnf-a levels screening gerps inflammation genes revealed mitogen-activated protein kinase kinase kinase kinase map4k4 previously unknown mediator cytokine expression importantly silencing map4k4 macrophages vivo protected mice lipopolysaccharide-induced lethality inhibiting tnf-alpha interleukin- beta production technology defines new strategy oral delivery sirna attenuate inflammatory responses human disease 
